Tromsø, Norway, August 14, 2025 - ArcticZymes Technologies (OSE: AZT) today
announced its financial results for the second quarter of 2025, highlighting
progress in the Company's commercial transformation. Total revenues reached NOK
28.9 million, up 5% year-over-year, led by strong 52% growth in the
Biomanufacturing segment which contributed NOK 18.1 million. The quarter also
marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a
product developed in direct response to customer needs. M-SAN HQ GMP enables
broader integration into viral vector manufacturing and reinforces ArcticZymes'
role as a reliable partner in gene therapy workflows.
Key Financials (Q2 and H1 2025):
· Total revenue: NOK 28.9 million, up 5% from NOK 27.5 million in Q2 2024. H1
2025 total revenues are at NOK 53.8 million, down 7% from NOK 57.6 million in H1
2024.
· Sales revenue: NOK 26.8 million, up 1%, compared to NOK 26.5 million in the
same quarter last year. H1 2025 sales are at NOK 50.0 million, down 13% from NOK
56.5 million in H1 2024.
· Revenue mix: Biomanufacturing contributed 68% (NOK 18.1 million); Molecular
Tools 32% (NOK 8.8 million) in Q2 2025
· EBITDA: Up 50% to NOK 3.9 million (Q2 2024: NOK 2.6 million). H1 2025 EBITDA
at NOK 0.1 (H1 2024: NOK 4.9 million).
Business Segment highlights
· Biomanufacturing momentum:
· Q2 2025 sales reached NOK 18.1 million, up 52% year-over-year (Q2 2024:
NOK 11.9 million) and 33% quarter-over-quarter (Q1 2025: NOK 13.6 million). H1
2025 Biomanufacturing revenues totalled NOK 31.4 million, a 32% increase over H1
2024 (NOK 23.6 million), marking the strongest first-half performance since
2022.
· Growth was driven by increased adoption of M-SAN HQ, continued onboarding
of new customers, and early integration into CDMO production workflows - all
reflecting strong execution of AZT's customer-centric strategy.
· M-SAN HQ GMP launched:
· Unlocking future high-value opportunities in gene therapy and viral vector
production
· First commercial orders shipped to customers
· Product mix:
· M-SAN HQ became the Company's top-selling product with a 62% increase over
the previous highest quarter and 130% growth over last year
· CDMO traction:
· AZT recognized initial revenues from a CDMO partner integrating M-SAN into
its production protocol
· Molecular Tools:
· Revenues declined 42% year-over-year and 11% sequentially, reflecting the
temporary absence of orders from a key customer.
· Encouragingly, this customer placed new purchase orders totalling nearly
NOK 16 million from Q3 and onwards, with deliveries and revenue recognition
scheduled across the next three quarters supporting a recovery in the second
half of the year.
CEO Commentary
"Q2 marked continued execution of our customer-centric strategy - one rooted in
partnership, providing solutions, and supporting our customers in achieving
their goals," said Michael Akoh, CEO of ArcticZymes Technologies. "In
Biomanufacturing, we're seeing growing adoption as more customers integrate our
Salt Active Nucleases into their workflows. The successful launch of GMP-grade M
-SAN HQ is a clear example of how we're responding to customer needs - providing
a product they can rely on from early research through to the commercialization
of their therapies. It has already unlocked new opportunities and is helping
deepen our role as a long-term partner.
"In Molecular Tools, while one key customer paused orders earlier in the year,
we're encouraged by their renewed commitment, including NOK 16 million in new
orders to be executed in the coming quarters, as well as growth from other
accounts. These results reflect not just strong execution, but real progress in
becoming a trusted partner to our customers - and in building a business
positioned for sustainable, long-term value creation for shareholders," said
Michael Akoh, CEO of ArcticZymes Technologies.
Outlook
For the second half of 2025, ArcticZymes anticipates:
· Continued momentum in Biomanufacturing
· Further adoption of GMP-grade M-SAN HQ and SAN HQ neo GMP
· Expanded engagement with platform CDMOs expected to start showing real
momentum in 2026 and onwards
· Recovery in Molecular Tools revenues supported by a robust order backlog
With a healthy cash position, no debt, and a growing commercial pipeline, the
Company remains focused on commercial execution, operational discipline,
strategic innovation, and delivering sustainable, profitable growth.
-Ends-
Presentation and Webcast
The Company will host a virtual Q2 and H1 2025 presentation for investors,
analysts and media at 8:30 CET on Thursday, August 14, 2025.
The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and VP
Sales and Marketing Paul Blackburn.
The presentation can be followed as a live webcast from Hegnar TV on
https://channel.royalcast.com/webcast/hegnarmedia/20250814_2 or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.
The report for Q2 and 1H 2025 will be available on www.newsweb.no and on the
company's homepage www.arcticzymes.com from 07.00 CET on Thursday, August 14,
2025.
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel:+47 95 29 01 87
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005. Its headquarters are based in
Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com